Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

Biosimilar Antibodies

BioVision is excited to offer a range of research grade Biosimilar Monoclonal Antibodies.

What exactly are Biosimilars and why are they so important?
According to the US Food and Drug Administration (FDA) definition, Biosimilars are biological products such as drugs, proteins, peptides and monoclonal antibodies that are very similar in safety, purity and efficacy to that of US FDA approved original innovative medicinal products. Biosimilars have the same active biological component as the original medicinal product. However, they are different in terms of inactive components and methods of production. In contrast to original medicinal product, Biosimilars are allowed to have only minor changes in their inactive components, which involves extensive analytical studies. This includes the study of structure and function of biological product, determination of toxicity, and pharmacological studies involving the assessment of pharmacokinetic and pharmacodynamic profile.

Biosimilars are expected to play a very important role in the treatment of several diseases such as cancer, haematologic and autoimmune diseases. Due to increased number of approvals for Biosimilars by US FDA, patients have additional options for medicines at a cheaper cost. This significantly reduces the cost of healthcare, and offsets the costs of buying the original patented medicinal product.

Are Biosimilars different from Generic drugs?
Biosimilars and Generic drugs are different brand names for the same original innovative medicinal product. Although both are aimed at providing affordable treatment options for patients, their development and approval process avoid replicating the lengthy and expensive process of clinical trials. Generics are usually small molecule drugs that are prepared through a series of chemical reactions in such a way that they will give exact identical copies of original medicinal product. Biosimilars are large biological molecules that are produced by living cells and involves several steps of cloning, cell line maintenance and expansion, product isolation, purification and characterisation. Due to constant changes in living cells, it is very difficult to produce identical copies of Biosimilars

What are Biosimilar Monoclonal Antibodies?
Biosimilar Monoclonal Antibodies are large complex proteins that are produced by living organisms. These antibodies help the immune system to fight diseases such as cancer, haematologic and autoimmune diseases by way of identification and neutralization of foreign microorganisms such as virus and bacteria. Due to expiration of patents of some of the blockbuster drugs, Biosimilar Monoclonal Antibodies are becoming increasingly popular in recent years. They are predicted to be the global leaders in the field of biopharmaceuticals. Hence, to support the customer’s Biosimilar-based research programs, BioVision offers Biosimilar Monoclonal Antibodies that have wide variety of research applications.

 

Features & Benefits

Research-grade antibodies prepared in PBS
Low endotoxicity
Highly pure (˃98%)
Used for drug potency assay development and identification of pre-clinical leads
Bulk quotes available


Biosimilar Antibodies

39 Item(s)

per page

39 Item(s)

per page